BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16419003)

  • 21. The value of electron microscopy in the diagnosis and clinical management of lupus nephritis.
    Herrera GA
    Ultrastruct Pathol; 1999; 23(2):63-77. PubMed ID: 10369101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lupus nephritis--clinical and morfological correlation].
    Banković N; Blagojević R; Jovanović D; Sindjić M; Pavlović S; Stojković D; Djukanović Lj
    Srp Arh Celok Lek; 1994; 122(7-8):215-7. PubMed ID: 17974390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus].
    Serikova SIu; Kozlovskaia NL; Shilov EM
    Ter Arkh; 2008; 80(6):52-8. PubMed ID: 18655477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic lupus erythematosus.
    Manson JJ; Rahman A
    Orphanet J Rare Dis; 2006 Mar; 1():6. PubMed ID: 16722594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.
    Faurschou M; Starklint H; Halberg P; Jacobsen S
    J Rheumatol; 2006 Aug; 33(8):1563-9. PubMed ID: 16881113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumothoraces complicating systemic lupus erythematosus with nephritis.
    Wilhelm M; Van Why SK
    Pediatr Nephrol; 2002 Apr; 17(4):261-3. PubMed ID: 11956878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous cyclophosphamide in lupus nephritis.
    Leondike MR; Shattuck MA
    J Intraven Nurs; 1993; 16(1):23-7. PubMed ID: 8437043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The longterm prognosis of lupus nephritis: the impact of disease activity.
    Goulet JR; MacKenzie T; Levinton C; Hayslett JP; Ciampi A; Esdaile JM
    J Rheumatol; 1993 Jan; 20(1):59-65. PubMed ID: 8441167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis.
    Trendelenburg M; Lopez-Trascasa M; Potlukova E; Moll S; Regenass S; Frémeaux-Bacchi V; Martinez-Ara J; Jancova E; Picazo ML; Honsova E; Tesar V; Sadallah S; Schifferli J
    Nephrol Dial Transplant; 2006 Nov; 21(11):3115-21. PubMed ID: 16877491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical course of end-stage renal disease in systemic lupus erythematosus.
    Jarrett MP; Santhanam S; Del Greco F
    Arch Intern Med; 1983 Jul; 143(7):1353-6. PubMed ID: 6870409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed lupus nephritis.
    Varela DC; Quintana G; Somers EC; Rojas-Villarraga A; Espinosa G; Hincapie ME; McCune WJ; Cervera R; Anaya JM
    Ann Rheum Dis; 2008 Jul; 67(7):1044-6. PubMed ID: 18413438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
    Tan Y; Yu F; Yang H; Chen M; Fang Q; Zhao MH
    Hum Immunol; 2008 Dec; 69(12):840-4. PubMed ID: 18852001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical approach to lupus nephritis: recent advances.
    Molino C; Fabbian F; Longhini C
    Eur J Intern Med; 2009 Sep; 20(5):447-53. PubMed ID: 19712841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A histochemical evaluation of thrombocyte metabolism in systemic lupus erythematosus].
    Kozlovskaia NL; Artem'eva VB; Kuznetsov SL; Kabaenkova GS; Kozlovskaia LV
    Ter Arkh; 1994; 66(6):35-6. PubMed ID: 7940363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis.
    Adhya Z; Borozdenkova S; Karim MY
    Nephrol Dial Transplant; 2011 Oct; 26(10):3273-80. PubMed ID: 21372259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?
    Giannico G; Fogo AB
    Clin J Am Soc Nephrol; 2013 Jan; 8(1):138-45. PubMed ID: 22977215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and pathological study of lupus nephritis without clinical renal involvement].
    Miyata M
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1051-8. PubMed ID: 8230815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New perspectives in the classification and treatment of systemic lupus erythematosus: the central role of kidney involvement].
    Cavagna L; Scorletti E; Romano M; Cagnotto G; Caporali R
    G Ital Nefrol; 2013; 30(4):. PubMed ID: 24403199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
    Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
    Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.